Comparative Pharmacology
Head-to-head clinical analysis: DEXLANSOPRAZOLE versus FLUXID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXLANSOPRAZOLE versus FLUXID.
DEXLANSOPRAZOLE vs FLUXID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Proton pump inhibitor that suppresses gastric acid secretion by specific inhibition of the (H+, K+)-ATPase enzyme system at the secretory surface of the gastric parietal cell.
FLUXID is a selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity by blocking the reuptake of serotonin at the presynaptic neuronal membrane, increasing serotonin availability in the synaptic cleft.
30 mg orally once daily for 4 weeks for healing of erosive esophagitis; maintenance therapy: 30 mg orally once daily for up to 6 months. For GERD: 30 mg orally once daily for 4 weeks.
1-2 g IV every 8 hours; maximum 6 g/day.
None Documented
None Documented
Clinical Note
moderateDexlansoprazole + Clodronic acid
"The therapeutic efficacy of Clodronic acid can be decreased when used in combination with Dexlansoprazole."
Clinical Note
moderateDexlansoprazole + Alendronic acid
"The therapeutic efficacy of Alendronic acid can be decreased when used in combination with Dexlansoprazole."
Clinical Note
moderateDexlansoprazole + Technetium Tc-99m medronate
"The therapeutic efficacy of Technetium Tc-99m medronate can be decreased when used in combination with Dexlansoprazole."
Clinical Note
moderate1-2 hours; clinical context: duration of acid suppression exceeds half-life due to binding to proton pumps
Terminal half-life: 12 hours (range 10–14 hours). In renal impairment (CrCl <30 mL/min), half-life prolonged to 24–36 hours; dose adjustment required.
Renal: 0% unchanged; metabolites eliminated via urine (51%) and feces (48%)
Renal: 70% unchanged; Fecal: 20%; Biliary: 10%.
Category A/B
Category C
Proton Pump Inhibitor
Proton Pump Inhibitor
Dexlansoprazole + Pamidronic acid
"The therapeutic efficacy of Pamidronic acid can be decreased when used in combination with Dexlansoprazole."